EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants

Yibo Zhou iD, Xing Meng, Jianhua Li, Gang Zeng, Jin Wang, Yunlong Cao iD, Chaoying Hu iD, Ronghua Jin iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00568-25 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Yibo Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Research Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Neutralizing, Antibodies, Viral, Antibodies, Monoclonal. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sinovac Biotech Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and serum neutralizing activity of a single dose of SA55 injection in healthy individuals. A randomized, controlled, double-blind trial was conducted with 40 healthy volunteers aged 18–65 years. Participants received a single intramuscular injection of the investigational product at four dose levels (150 mg, 300 mg, 600 mg, and 900 mg), with randomization stratified by dose cohort. Dose proportionality and linearity of PK parameters (AUC 0-∞ , AUC 0-t , and C max ) were assessed using one-way ANOVA and the Power model, while neutralizing the activity against the EG.5 strain, and safety outcomes were monitored. Results demonstrated that SA55 injection was safe and well-tolerated at doses ranging from 150 mg to 900 mg, with a half-life of 94–103 days and no significant dose-dependent trends. C max , AUC 0-t , and AUC 0-∞ showed an approximately linear relationship with dosage, while T max decreased as the dosage increased. The levels of ADA of all positive participants were at low levels, and the cumulative positive rates among treatment groups were similar to that of the placebo group. The neutralizing activity peaked at 3–4 days post-administration, with the 600 mg dose exhibiting comparable activity to the 900 mg dose and superior activity to lower doses, suggesting it as a potential target dose. In conclusion, SA55 injection demonstrated excellent safety, tolerability, and neutralizing activity against SARS-CoV-2 in healthy populations, with the 600 mg dose emerging as a promising candidate for further development. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT06050460 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralAntibodies, MonoclonalHumansAdultMiddle AgedMaleFemaleDouble-Blind MethodHealthy VolunteersYoung AdultAdolescentAgedCOVID-19Injections, IntramuscularCOVID-19 Drug TreatmentArea Under CurveHalf-Life

Stichwörter der Autor:innen

SA55 injectionSARS-CoV-2monoclonal antibodypharmacokinetics

Substanzen

Antibodies, NeutralizingAntibodies, ViralAntibodies, Monoclonal

Autor:innen und Institutionen

  • Phase I Clinical Research Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Public Health Emergency Management Innovation Center, Beijing, China.
  • Clinical Research and Development Center Sinovac Biotech Co., Ltd., Beijing, China.
  • Zhejiang Key Laboratory of Public Health Detection and Pathogenesis Research, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
  • Changping Laboratory, Beijing, Beijing, China.

ORCID-Profile: Yibo Zhou, Yunlong Cao, Chaoying Hu, Ronghua Jin

Förderung

  • Sinovac Biotech Co., Ltd.

Zitieren

APA

Zhou, Y., Meng, X., Li, J., Zeng, G., Wang, J., Cao, Y., Hu, C., & Jin, R. (2025). Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00568-25

Vancouver

Zhou Y, Meng X, Li J, Zeng G, Wang J, Cao Y, et al. Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00568-25

BibTeX
@article{Zhou2025,
  author = {Zhou, Yibo and Meng, Xing and Li, Jianhua and Zeng, Gang and Wang, Jin and Cao, Yunlong and Hu, Chaoying and Jin, Ronghua},
  title = {Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00568-25}
}
Kostenlos starten →